Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and Older
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Influenza-associated morbidity and mortality has not decreased in the last decade, despite increased receipt of vaccine. To improve the immunogenicity of influenza vaccine, a high-dose (HD) trivalent, inactivated influenza vaccine was developed. METHODS: A multicenter, randomized, double-blind controlled study was conducted to compare HD vaccine (which contains 60 microg of hemagglutinin per strain) with the licensed standard-dose (SD) vaccine (which contains 15 microg of hemagglutinin per strain) in adults > or = 65 years of age. RESULTS: HD vaccine was administered to 2575 subjects, and SD vaccine was administered to 1262 subjects. There was a statistically significant increase in the rates of seroconversion and mean hemagglutination inhibition titers at day 28 after vaccination among those who received HD vaccine, compared with those who received SD vaccine. Mean postvaccination titers for individuals who received HD vaccine were 116 for H1N1, 609 for H3N2, and 69 for B strain; for those who received SD vaccine, mean postvaccination titers were as 67 for H1N1, 333 for H3N2, and 52 for B strain. The HD vaccine met superiority criteria for both A strains, and the responses for B strain met non-inferiority criteria. Seroprotection rates were also higher for those who received HD vaccine than for those who received SD vaccine vaccine, for all strains. Local reactions were more frequent in individuals who received HD vaccine, but the reactions were mild to moderate. CONCLUSIONS: There was a statistically significant increase in the level of antibody response induced by HD influenza vaccine, compared with that induced by SD vaccine, without an attendant increase in the rate or severity of clinically relevant adverse reactions. These results suggest that the high-dose vaccine may provide improved protective benefits for older adults. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00391053 .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All of the above formulations show slightly higher immunogenicity in the elderly compared to the standard trivalent inactivated vaccine.”
From Aging of the immune system: Focus on inflammation and vaccination (2016) · cites this paper as [161]
In the citing paper
“for some populations, such as older adults, a higher dose might be beneficial, as has been shown for the influenza vaccine69,70.”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [69]
Citations
Cites
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673 · cited 1×
“Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1–3].”
MethodInfluenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213 · cited 1×
“Although vaccination is an effective method for reducing influenza-associated morbidity and mortality, the rates of hospitalization and death due to seasonal influenza in elderly individuals have increased substantially in the past 2 decades despite increasing influenza vaccine coverage [1–3].”
MethodAntibody response to influenza vaccination in the elderly: A quantitative review
GOODWIN, K., VIBOUD, C., & SIMONSEN, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2005.08.105 · Cited by 1,064 · cited 2×
“vaccine effectiveness are generally lower in older adults [1, 4-6].”
BackgroundResultHobson, D., Curry, R. L., Beare, A. S., & Ward-Gardner, A. (1972) · Epidemiology and Infection · doi:10.1017/s0022172400022610 · Cited by 1,002 · cited 2×
“In addition, HAI titers correlate inversely with severity of illness and duration of viral shedding, with HAI titers of 1:40 conferring ∼50% protection against infection and higher levels associated with greater degrees of protection [24, 25].”
BackgroundGovaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Effectiveness of Influenza Vaccine in the Community-Dwelling Elderly
Nichol, K. L., Nordin, J. D., Nelson, D. B., Mullooly, J. P., & Hak, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070844 · Cited by 656 · cited 1×
“efficacy of currently licensed vaccines [1, 17].”
Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population
(2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.265 · Cited by 543 · cited 1×
“efficacy of currently licensed vaccines [1, 17].”
DETERMINANTS OF IMMUNITY TO INFLUENZA INFECTION IN MAN
POTTER, C. W., & OXFORD, J. S. (1979) · British Medical Bulletin · doi:10.1093/oxfordjournals.bmb.a071545 · Cited by 452 · cited 1×
“In addition, HAI titers correlate inversely with severity of illness and duration of viral shedding, with HAI titers of 1:40 conferring ∼50% protection against infection and higher levels associated with greater degrees of protection [24, 25].”
BackgroundVu, T., Farish, S., Jenkins, M., & Kelly, H. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00041-5 · Cited by 376 · cited 1×
“appears that efficacy is diminished in older age groups [18].”
BackgroundThe efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines
Nichol, K. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00070-7 · Cited by 265
Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons
Keitel, W. A., Atmar, R. L., Cate, T. R., Petersen, N. J., Greenberg, S. B., Ruben, F., & Couch, R. B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1121 · Cited by 187 · cited 1×
“In prior phase 1 and 2 studies involving medically stable, ambulatory adults 65 years old, high-dose (HD) vaccine induced significantly higher HAI titers than did SD vaccine, with minimal increased reactogenicity [11, 14].”
BackgroundTreanor, J. J., Mattison, H. R., Dumyati, G., Yinnon, A., Erb, S., O'Brien, D., Dolin, R., & Betts, R. F. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-8-625 · Cited by 167 · cited 1×
“[19–22].”
Self-citationSafety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects
Couch, R. B., Winokur, P., Brady, R., Belshe, R., Chen, W. H., Cate, T. R., Sigurdardottir, B., Hoeper, A., Graham, I. L., Edelman, R., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.08.042 · Cited by 167 · cited 1×
“In prior phase 1 and 2 studies involving medically stable, ambulatory adults 65 years old, high-dose (HD) vaccine induced significantly higher HAI titers than did SD vaccine, with minimal increased reactogenicity [11, 14].”
BackgroundSelf-citationPalache, A. M., BEYER, W. E. P., Sprenger, M. J. W., Masurel, N., de Jonge, S., Vardy, A., Charpentier, B., Noury, J., van Beek, W. C. A., Borst, R. J. A., et al. (1993) · Vaccine · doi:10.1016/0264-410x(93)90333-s · Cited by 91 · cited 1×
“dose-dependent increase in HAI antibodies [10-14].”
Ruben, F. L., & Jackson, G. G. (1972) · The Journal of Infectious Diseases · doi:10.1093/infdis/125.6.656 · Cited by 73 · cited 1×
“and they have had suboptimal responses to standard influenza vaccine [12, 23].”
BackgroundGorse, G. J., O’Connor, T., Young, S. L., Mendelman, P. M., Bradley, S., Nichol, K. L., Strickland, J. H., Paulson, D. M., Rice, K. L., Foster, R., et al. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00748-x · Cited by 66
Self-citationAntibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly
Bruijn, I. D., Meyer, I., Gerez, L., Nauta, J. J. P., Giezeman‐Smits, K. M., & Palache, B. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.10.051 · Cited by 65 · cited 1×
“[19–22].”
Masurel, N., & Laufer, J. (1984) · Journal of Hygiene · doi:10.1017/s0022172400064500 · Cited by 53 · cited 2×
“A consistent inverse quantitative relationship between HAI titer and risk of influenza infection has been observed in both experimental challenge and natural exposure studies [7–9].”
BackgroundImmunity to Influenza in Older Adults with Chronic Obstructive Pulmonary Disease
Gorse, G. J., O’Connor, T., Newman, F. K., Mandava, M. D., Mendelman, P. M., Wittes, J. T., & Peduzzi, P. N. (2004) · The Journal of Infectious Diseases · doi:10.1086/421121 · Cited by 52 · cited 2×
“A consistent inverse quantitative relationship between HAI titer and risk of influenza infection has been observed in both experimental challenge and natural exposure studies [7–9].”
BackgroundSelf-citationTreanor, J. J., Dumyati, G. K., O’Brien, D., Riley, M. A., Riley, G., Erb, S., & Betts, R. F. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.2.402 · Cited by 38
Self-citationMostow, S. R., Schoenbaum, S. C., Dowdle, W. R., Coleman, M. T., & Kaye, H. S. (1973) · Postgraduate Medical Journal · doi:10.1136/pgmj.49.569.152 · Cited by 31 · cited 1×
“dose-dependent increase in HAI antibodies [10-14].”
EVALUATION OF MONOVALENT INFLUENZA VIRUS VACCINES:
Meiklejohn, G., Weiss, D. L., SHRAGG, R. I., & Lennette, E. H. (1952) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a119498 · Cited by 12 · cited 2×
“A consistent inverse quantitative relationship between HAI titer and risk of influenza infection has been observed in both experimental challenge and natural exposure studies [7–9].”
Background
Cited by
Fiore, A. E., Uyeki, T. M., Broder, K. R., Finelli, L., Euler, G. L., Singleton, J. A., Iskander, J. K., Wortley, P. M., Shay, D. K., Bresee, J., et al. (2009) · PubMed · Cited by 2,076
Grohskopf, L. A., Sokolow, L. Z., Broder, K. R., Walter, E. B., Fry, A. M., & Jernigan, D. B. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6703a1 · Cited by 1,632
“Fluad (aIIV3) was more effective against laboratory-confirmed influenza than unadjuvanted SD-IIV3 among adults aged ≥65 years (N = 227; 165 of whom received aIIV3 and 62 IIV3) in an analysis from a small single-season observational study (60).”
InfluentialA guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Factors That Influence the Immune Response to Vaccination
Zimmermann, P., & Curtis, N. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00084-18 · Cited by 939
Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults
DiazGranados, C. A., Dunning, A. J., Kimmel, M., Kirby, D., Treanor, J., Collins, A., Pollak, R., Christoff, J., Earl, J., Landolfi, V., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315727 · Cited by 876
Self-citation
Metadata
- Authors
- Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J., & Gorse, G. J.
- Affiliations
- University of Rochester Medicine (US)
- St. Louis VA Medical Center (US)
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-15
- Volume
- 200
- Issue
- 2
- Pages
- 172-180
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2164949714
- Cited by
- 388
- References
- 22
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 12 · 2023: 20 · 2022: 15 · 2021: 24 · 2020: 25 · 2019: 33 · 2018: 25 · 2017: 22 · 2016: 23 · 2015: 25 · 2014: 32 · 2013: 34 · 2012: 24
- FWCI
- 13.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- high-dose influenza vaccine, standard-dose influenza vaccine, immunogenicity, older adults, seroconversion, hemagglutination inhibition titers, trivalent inactivated influenza vaccine, vaccine dose comparison, local adverse reactions, seroprotection rate
- MeSH terms
- Aged, Aged, 80 and over, Antibodies, Viral, Dose-Response Relationship, Immunologic, Double-Blind Method, Female, Humans, Influenza, Human, Influenza Vaccines, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.